Drug Search Results
More Filters [+]

ETBX-061

Alternative Names: etbx-061, etbx061, etbx 061
Latest Update: 2024-08-27
Latest Update Note: Clinical Trial Update

Product Description

Ad5 [E1-, E2b-]-MUC1. NANT Pancreatic Cancer Vaccine (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03586869)

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: ImmunityBio
Company Location: SAN DIEGO CA 92121
Company CEO: Richard Adcock
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ETBX-061

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Triple Negative Breast Cancer|Non-Small-Cell Lung Cancer|Hepatocellular Carcinoma|Lymphoma, Non-Hodgkin|Ovarian Cancer|Colorectal Cancer|Carcinoma, Merkel Cell|Squamous Cell Carcinoma|Head and Neck Cancer|Pancreatic Cancer|Chordoma|Melanoma|Transitional Cell Carcinoma

Phase 1: Prostate Cancer|Colorectal Cancer|Lung Cancer|Breast Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

QUILT-3.067

P2

Terminated

Triple Negative Breast Cancer

2020-09-11

QUILT-3.091

P2

Withdrawn

Chordoma

2020-08-31

56%

QUILT-3.091

P2

Withdrawn

Chordoma

2020-08-31

56%

QUILT-3.091

P2

Withdrawn

Chordoma

2020-08-31

56%

QUILT-3.091

P2

Withdrawn

Chordoma

2020-08-31

56%

TNBC

P2

Withdrawn

Triple Negative Breast Cancer

2020-06-01

31%

TNBC

P2

Withdrawn

Triple Negative Breast Cancer

2020-06-01

31%

TNBC

P2

Withdrawn

Triple Negative Breast Cancer

2020-06-01

31%

TNBC

P2

Withdrawn

Triple Negative Breast Cancer

2020-06-01

31%

TNBC

P2

Withdrawn

Triple Negative Breast Cancer

2020-06-01

31%

18-C-0073

P1

Completed

Prostate Cancer

2020-01-15

Recent News Events